Log in

Relevant bibliographies by topics / RSA advisors/referents / Journal articles

To see the other types of publications on this topic, follow the link: RSA advisors/referents.

Journal articles on the topic 'RSA advisors/referents'

Author: Grafiati

Published: 15 June 2024

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'RSA advisors/referents.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Carande, Robert. "Reference Advisory Systems (RAS): Some Practical Issues." Reference Services Review 17, no. 3 (1989): 87–90. http://dx.doi.org/10.1108/eb049069.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Ambrogi, Federica. "Elisa Paini (1863-1924). Wife and «unbeatable collaborator» of Luigi Credaro." Rivista di Storia dell’Educazione 7, no. 2 (2020): 133–44. http://dx.doi.org/10.36253/rse-9865.

Full text

Abstract:

The life of Luigi Credaro’s wife, Elisa Paini, allows us to observe some aspects of Credaro’s life in a new light. Through unpublished archival documents and letters of the spouses, the role of his wife is revealed, who was not only a trusted advisor but also a very reserved collaborator of the “Rivista Pedagogica” [Educational Journal] and the Unione Magistrale Nazionale, the Elementary school teachers national union. Elisa also represented the reference point for Credaro’s friends and colleagues and for anyone who wanted to reach him, to such an extent that she replaced her husband in his wr

APA, Harvard, Vancouver, ISO, and other styles

3

Walker, Christopher J., Junke Wang, Alyssa I. Clay-Gilmour, et al. "Meta-Analysis of Genome-Wide Association Studies of Acute Myeloid Leukemia (AML) Patients Identifies Variants Associated with Risk of 11q23/KMT2A-Translocated and Core-Binding Factor (CBF) AML and Suggests a Role for Transcription Elongation in Leukemogenesis." Blood 136, Supplement 1 (2020): 29–30. http://dx.doi.org/10.1182/blood-2020-141653.

Full text

Abstract:

The first three authors contributed equally. The last three authors share senior authorship. Background: Although there has been an increased recognition of the contribution of germline variants to development of myeloid neoplasms, only two large-scale case-control genome-wide association studies (GWASs) have been conducted to identify variants that predispose to AML. Importantly, these studies were dedicated to AML predisposition in general, without investigation of molecularly distinct AML subtypes. Thus, we performed the first dedicated meta-analysis combining the two GWASs to investigate p

APA, Harvard, Vancouver, ISO, and other styles

4

Visconte, Valeria, Bartlomiej P. Przychodzen, Vera Adema, et al. "Development of a Novel Class of Agents Targeting the RNA-Splicing Machinery in Myeloid Malignancies." Blood 132, Supplement 1 (2018): 211. http://dx.doi.org/10.1182/blood-2018-99-116411.

Full text

Abstract:

Abstract SF3B1 is a splicing factor gene whose mutations are pathognomonic of MDS with ring sideroblasts. Because of the ubiquitous importance of splicing, a major barrier in targeting cells with spliceosomal mutations is the discovery of agents decreasing the competitiveness of mutant cells while preserving the integrity of wild type cells. To date no specific therapies are FDA approved for SF3B1 mutant (SF3B1MT) MDS and few agents are in early clinical testing. We describe a novel targeted approach to drug development for SF3B1MT malignancies. Our investigative strategy started with a high t

APA, Harvard, Vancouver, ISO, and other styles

5

Yalniz, Fevzi F., Rima M. Saliba, Orhan K. Yucel, et al. "Somatic Mutations Improve Risk Classification By Cytogenetic Abnormalities in Patients with Myelodysplastic Syndrome after Hematopoietic Stem Cell Transplantation." Blood 134, Supplement_1 (2019): 512. http://dx.doi.org/10.1182/blood-2019-125937.

Full text

Abstract:

Background: Hematopoietic stem cell transplantation (HSCT) offers potentially curative therapy for patients with myelodysplastic syndrome (MDS) but disease progression after HSCT remains a major reason for failure after transplant. Identification of risk factors for progression of MDS after HSCT would allow to identify target population for early initiation of preventive treatments to improve outcomes. Methods: Patients with a diagnosis of MDS who received first HSCT between 2013 and 2018 with available pre-transplant genetic profile obtained from next generation sequencing of genes were inclu

APA, Harvard, Vancouver, ISO, and other styles

6

Murphy, Tracy, Stanley W. K. Ng, Tong Zhang, et al. "Trial in Progress: Feasibility and Validation Study of the LSC17 Score in Acute Myeloid Leukemia Patients." Blood 134, Supplement_1 (2019): 2682. http://dx.doi.org/10.1182/blood-2019-130532.

Full text

Abstract:

Background: AML is driven by a small subpopulation of leukemia stem cells (LSCs), which possess stem-cell properties such as quiescence and self-renewal that are linked to therapy resistance and relapse. The LSC17 score was derived from genes differentially expressed between functionally validated LSC+ and LSC- cell fractions from 78 AML patients. The LSC17 score was strongly associated with survival in 4 independent cohorts of AML patients treated with curative intent (n = 908), and accurately predicted initial response. Patients with high LSC17 scores had poor outcomes with standard treatmen

APA, Harvard, Vancouver, ISO, and other styles

7

Mahevas, Matthieu, Stephanie Guillet, Jean-Francois Viallard, et al. "Rate of Prolonged Response after Stopping Thrombopoietin-Receptor Agonists Treatment in Primary Immune Thrombocytopenia (ITP): Results from a Nationwide Prospective Multicenter Interventional Study (STOPAGO)." Blood 138, Supplement 1 (2021): 583. http://dx.doi.org/10.1182/blood-2021-152767.

Full text

Abstract:

Abstract Background: Thrombopoietin receptor agonists(TPO-RAs) have been thought to play only a supporting role in ITP management. Several retrospective studies and a recent prospective study have reported unexpected cases of durable remission after TPO-RAs discontinuation in adult ITP in up to 30%. However, newly diagnosed ITP cases for which spontaneous remission may occur have been included in most of these studies. Thus, the main purpose of this study was to determine the proportion of patients with either persistent or chronic phase and no recent exposure to any potentially curative thera

APA, Harvard, Vancouver, ISO, and other styles

8

Tomaz, Victória, Karina Griesi-Oliveira, Renato D. Puga, Fabio Pires de Souza Santos, Nelson Hamerschlak, and Paulo Vidal Campregher. "Identification of Gene Networks Associated with the Anti-Leukemic Effect of Anti-Inflammatory Drugs on Acute Myeloid Leukemia Cell Lines." Blood 138, Supplement 1 (2021): 4343. http://dx.doi.org/10.1182/blood-2021-153903.

Full text

Abstract:

Abstract Introduction Despite recent advances in therapy, acute myeloid leukemia (AML) remain a medical challenge with high morbidity and mortality rates. For most patients, allogeneic hematopoietic stem cell transplantation remain the only curative option, but due to the advanced age at diagnosis, a significant proportion of patients are not elegible to this form of therapy. Nevertheless, novel therapies are warranted. There is preclinical evidence that anti-inflammatory compounds, such as COX-2 inhibitors and steroids, may have anti-neoplastic activity in different tumor types, including AML

APA, Harvard, Vancouver, ISO, and other styles

9

Yao, Lijun, Reyka G. Jayasinghe, Beena E. Thomas, et al. "Integrated Cytof, Scrna-Seq and Cite-Seq Analysis of Bone Marrow Immune Microenvironment in the Mmrf Commpass Study." Blood 136, Supplement 1 (2020): 28–29. http://dx.doi.org/10.1182/blood-2020-142534.

Full text

Abstract:

Compared with traditional bulk sequencing technologies, single-cell technologies have advantages to evaluate cellular heterogeneity and investigate the evolution of cellular subpopulations from the tumor and microenvironment. Application of single-cell sequencing in Multiple Myeloma (MM) is especially beneficial given MM is a highly heterogeneous disease with uncontrolled clonal expansion of plasma cells. Single-cell RNA sequencing (scRNA-seq) has been previously utilized to understand this hematopoietic malignancy in both tumor and immune populations in MM (Ledergor G. et al., 2018, Zavidij,

APA, Harvard, Vancouver, ISO, and other styles

10

Perumal, Deepak, Alessandro Lagana', Alex Rubinsteyn, et al. "Patient-Specific Mutation-Derived Tumor Antigens As Targets for Cancer Immunotherapy in Multiple Myeloma." Blood 126, no. 23 (2015): 1851. http://dx.doi.org/10.1182/blood.v126.23.1851.1851.

Full text

Abstract:

Abstract Multiple myeloma (MM) is an incurable plasma cell malignancy accounting for more than 10,000 deaths in the US each year. Novel therapeutic approaches for relapsed MM are urgently needed. Tumor-specific mutations are ideal targets for cancer immunotherapy as they can be potentially recognized as neo-antigens by mature T-cells. Targeting tumor-specific antigens harboring somatic mutations presented on major histocompatibility complex class I molecules (MHC-I) with peptides could personalize the therapeutic approach for relapsed patients. To test this possibility, we examined 6 relapsed

APA, Harvard, Vancouver, ISO, and other styles

11

Pelham, Robert J., Xuguang Hu, Philippe Moreau, et al. "Genomic Predictors of Progression-Free Survival Among Patients with Relapsed or Refractory Multiple Myeloma Treated with Carfilzomib and Dexamethasone or Bortezomib and Dexamethasone in the Phase 3 Endeavor Trial." Blood 130, Suppl_1 (2017): 839. http://dx.doi.org/10.1182/blood.v130.suppl_1.839.839.

Full text

Abstract:

Abstract Background: In the phase 3 ENDEAVOR trial, treatment with carfilzomib administered at 56 mg/m2 twice weekly in combination with dexamethasone (Kd56) significantly improved progression-free survival (PFS) compared to treatment with bortezomib and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma (RRMM) (Dimopoulos MA, et al. Lancet Oncol . 2016;17:27-38). In this substudy of ENDEAVOR, we used whole transcriptome RNA sequencing (RNA-seq) to identify genes whose baseline expression levels in CD138+ cells were predictive of PFS in patients treated with Kd56 or Vd

APA, Harvard, Vancouver, ISO, and other styles

12

Mageau, Arthur, Louis Terriou, Mikael Ebbo, et al. "Splenectomy for Primary Immune Thrombocytopenia Revisited at the Era of Thrombopoietin Receptor Agonists: New Insights for an Old Treatment." Blood 138, Supplement 1 (2021): 17. http://dx.doi.org/10.1182/blood-2021-147450.

Full text

Abstract:

Abstract Introduction Although splenectomy is still considered as the most effective curative treatment for primary immune thrombocytopenia (ITP), its use has significantly declined in the last decade, especially since the emergence of thrombopoietin receptor agonist (TPO-RAs) and anti-CD20 monoclonal antibodies 1-3. The main objective of our study was to evaluate if splenectomy was still as effective in the modern era, particularly for patients who failed to respond to TPO-RAs and rituximab. One of the secondary objectives was to assess, among patients who did not respond to or relapse after

APA, Harvard, Vancouver, ISO, and other styles

13

Brummaier, Tobias, Basirudeen Syed Ahamed Kabeer, Stephen Lindow, et al. "A prospective cohort for the investigation of alteration in temporal transcriptional and microbiome trajectories preceding preterm birth: a study protocol." BMJ Open 9, no. 1 (2019): e023417. http://dx.doi.org/10.1136/bmjopen-2018-023417.

Full text

Abstract:

IntroductionPreterm birth (PTB) results from heterogeneous influences and is a major contributor to neonatal mortality and morbidity that continues to have adverse effects on infants beyond the neonatal period. This protocol describes the procedures to determine molecular signatures predictive of PTB through high-frequency sampling during pregnancy, at delivery and the postpartum period.Methods and analysisFour hundred first trimester pregnant women from either Myanmar or Thailand of either Karen or Burman ethnicity, with a viable, singleton pregnancy will be enrolled in this non-interventiona

APA, Harvard, Vancouver, ISO, and other styles

14

Croucher, Danielle C., Marta Chesi, Zhihua Li, et al. "A Single-Cell Transcriptional Analysis of Tumour Cells and the Immune Microenvironment during Disease Evolution in a Transgenic Mouse Model of Myeloma." Blood 132, Supplement 1 (2018): 56. http://dx.doi.org/10.1182/blood-2018-99-118691.

Full text

Abstract:

Abstract Introduction: Multiple Myeloma (MM) is consistently preceded by pre-malignant asymptomatic monoclonal gammopathies (AMG). To date, our understanding of the pathogenesis of progression to MM remains incomplete. Genetic analyses of AMG cells compared to MM-derived plasma cells (PCs) have found few differences, suggesting that progression may be mediated in part by tumour-extrinsic mechanisms. To comprehensively examine the cellular and molecular complexities of MM pathogenesis, we performed an unbiased single cell RNA-sequencing (scRNA-seq) analysis of tumour cells as well as immune cel

APA, Harvard, Vancouver, ISO, and other styles

15

Nicolini, Franck E., Vincent Alcazer, Stephanie Dulucq, et al. "The Outcome of Treatment-Free Remission after First-Line Nilotinib or Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients Is Different." Blood 138, Supplement 1 (2021): 2552. http://dx.doi.org/10.1182/blood-2021-146722.

Full text

Abstract:

Abstract Aims: The absolute number of chronic phase CML patients (pts) reaching the treatment-free remission (TFR) criteria has been substantially increased by the use of second-generation TKI (TKI2), initiated since diagnosis, comparing to Imatinib first-line. However, the relative rate of unsuccessful TFR (i. e. pts loosing their MMR after TKI2 cessation) still remains around 50% at 2 years and beyond, whatever the TKI2 was. The aim of this study is to analyse the rate of successful TFR in pts receiving Nilotinib (Nilo) or Dasatinib (Dasa) first-line obtaining the appropriate criteria. Metho

APA, Harvard, Vancouver, ISO, and other styles

16

Roeser, Anais, Guillaume Moulis, Mikael Ebbo, et al. "A Retrospective Multicenter Case Study Evaluating the Characteristics, Management and Outcome of Acquired Amegakaryocytic Thrombocytopenia." Blood 138, Supplement 1 (2021): 3167. http://dx.doi.org/10.1182/blood-2021-153388.

Full text

Abstract:

Abstract Introduction Acquired amegakaryocytic thrombocytopenia (AAT) is an extremely rare disease characterized by acquired megakaryocytic aplasia or hypoplasia with no other lineage abnormalities. Given limited evidence, the first aim of this study was to describe the characteristics, management and outcome of patients with AAT, the second aim was to examine the therapeutic response through a systematic review of published case reports. Patients and Methods We carried out a retrospective multicenter study through the French Reference Network for Adult Autoimmune Cytopenias, including patient

APA, Harvard, Vancouver, ISO, and other styles

17

Slashcheva, Natalia, and Elena Beskaravainaya. "Information Needs and Media and Information Literacy of Modern Researchers." Science Management: Theory and Practice 7, no. 2 (2025): 114–28. https://doi.org/10.19181/smtp.2025.7.2.6.

Full text

Abstract:

The Library for Natural Sciences of the RAS (LNS RAS) has always paid great attention to analyzing information needs of users. In 2024, a study was conducted to collect data about information services for various categories of users. For this purpose, a survey was developed containing questions about job positions and age groups of the respondents, ways to obtain scientometric data, as well as other additional services that can be provided to users of the scientific library. The number of respondents who took part in the study was 108 people. The survey demonstrated the interest of all categor

APA, Harvard, Vancouver, ISO, and other styles

18

Bloehdorn, Johannes, Julia Krzykalla, Billy Michael Chelliah Jebaraj, et al. "MYC Pathway Activation Is Frequently Observed in Treatment-Naive CLL and Defines a Subgroup with Particular Benefit from the Addition of Rituximab to Chemotherapy." Blood 132, Supplement 1 (2018): 1866. http://dx.doi.org/10.1182/blood-2018-99-116937.

Full text

Abstract:

Abstract Background: The MYC proto-oncogene encodes a DNA-binding factor that can induce widespread changes in gene expression profiles (GEP). Activation of MYC is a hallmark of aggressive lymphomas and frequently observed in Richter transformation of CLL. In contrast, the role of MYC-related pathogenic networks is less clearly defined in untransformed CLL. Aims: We hypothesized that MYC activation in CLL could lead to specific GEP associated with aggressive disease. We combined the analysis of genomic copy number alterations (CNA) and GEP involved in MYC pathway activation on specimens from p

APA, Harvard, Vancouver, ISO, and other styles

19

Murphy, Tracy, Stanley W. K. Ng, Ian King, et al. "Inferior Outcomes with a High LSC17 Score Can be Improved with Flag-IDA." Blood 136, Supplement 1 (2020): 35–36. http://dx.doi.org/10.1182/blood-2020-138943.

Full text

Abstract:

Introduction: Acute myeloid leukemia (AML) is driven by a subpopulation of leukemia stem cells (LSCs), which possess properties such as quiescence and self-renewal that are linked to therapy resistance and relapse. The LSC17 score was derived from genes differentially expressed between functionally validated LSC+ and LSC- fractions from 78 AML patients and is strongly associated with survival and response to standard therapy. A critical advantage of the LSC17 test over cytogenetic and molecular analysis is its rapid turnaround time (24-48h on a NanoString platform), providing clinicians with a

APA, Harvard, Vancouver, ISO, and other styles

20

van Beers, Erik H., Martin H. Van Vliet, Kenneth C. Anderson, et al. "High Risk Multiple Myeloma Cases Are Identified In An MMRC Led Study By The SKY92 Gene Signature (MMprofiler)." Blood 122, no. 21 (2013): 1854. http://dx.doi.org/10.1182/blood.v122.21.1854.1854.

Full text

Abstract:

Abstract Introduction Multiple Myeloma is not a single disease. There is increasing support for risk classification in combination with treatment decision making because of its impact on clinical outcomes. Here we demonstrate additional evidence of the prognostic value of SKY92, an established genetic marker of high risk Multiple Myeloma in a multicenter collection of samples with undisclosed treatments. Materials Methods A public GEP dataset (MMRC, MMGI portal) contained 114 cases of untreated Multiple Myeloma and was used for SKY92 high risk OS prediction (Kuiper et al. Leukemia 2012). In co

APA, Harvard, Vancouver, ISO, and other styles

21

Fulciniti, Mariateresa, Charles Y. Lin, Mehmet K. Samur, et al. "Discovery and Characterization of Promoter and Super-Enhancer-Associated Dependencies through E2F and BET Bromodomains in Multiple Myeloma." Blood 126, no. 23 (2015): 838. http://dx.doi.org/10.1182/blood.v126.23.838.838.

Full text

Abstract:

Abstract Recently we reported the concomitant inhibition of MYC and E2F activity in multiple myeloma (MM) upon treatment with the BET bromodomain inhibitor JQ1. BET bromodomains (BETs) are transcriptional co-activators that occupy active promoters and enhancers, but are asymmetrically localized to a small number of "super-enhancer" domains. JQ1 treatment results in disproportionate displacement of BETs from super-enhancers leading to potent and selective downregulation of super-enhancer target genes, with MYC levels > 90% depleted after 6 hours. In contrast, E2F protein levels are relativel

APA, Harvard, Vancouver, ISO, and other styles

22

Asmann, Yan, Ying Li, Taxiarchis Kourelis, et al. "Single Cell Transcriptome Profile of Myeloma and Immune Cell Characteristics in Patients with Durable Response Post CART." Blood 138, Supplement 1 (2021): 3838. http://dx.doi.org/10.1182/blood-2021-153254.

Full text

Abstract:

Abstract Background: Chimeric antigen receptor T cell therapy (CAR-T) is a recent therapeutic advance for the treatment of myeloma. Among the FDA approved and investigational CAR-T, primary refractory disease post CAR-T infusion is uncommon, however most patients eventually relapse. To gain insight to the myeloma cell and immune cell characteristics associated with early relapse (PD) versus durable response (DR), we examined myeloma cells and immune cells in both the bone marrow and blood by single cell RNA-seq. Method: Bone marrow aspirate and blood samples were collected prior to BCMA target

APA, Harvard, Vancouver, ISO, and other styles

23

Catalano, Calogerina, Joanna Blocka, Stefanie Huhn, et al. "Characterization of Rare Germline Variants in Familial Multiple Myeloma." Blood 136, Supplement 1 (2020): 45–46. http://dx.doi.org/10.1182/blood-2020-142253.

Full text

Abstract:

Introduction: The risk of developing Multiple Myeloma (MM) is 2-4 fold higher in first-degree relatives of patients with MM compared to the general population, suggesting genetic predisposition to this cancer. Indeed, recent genome-wide association studies have identified common risk alleles that predispose for MM. Yet, the impact of these variants on MM risk is too low to explain familial aggregation of MM. High-impact alleles have been identified for other cancers such as ovarian and breast cancer (BRCA1,-2) and melanoma (CDKN2A) but the search for such alleles in MM is still in its infancy.

APA, Harvard, Vancouver, ISO, and other styles

24

Tirier, Stephan M., Jan-Philipp Mallm, Nicola Casiraghi, et al. "Dissecting Heterogeneity of Tumor Cells and Their Microenvironment in Refractory Multiple Myeloma." Blood 134, Supplement_1 (2019): 571. http://dx.doi.org/10.1182/blood-2019-128625.

Full text

Abstract:

Introduction: Despite significant improvements in therapy during the last decade, most multiple myeloma (MM) patients develop refractory disease over time. Treatment of refractory MM is a major challenge, likely due to the still poorly characterized inter- and intratumor heterogeneity at this stage of the disease, and the complex interplay of MM cells with the microenvironment (ME). In particular, there is an urgent need to unravel how these features of MM are linked to molecular mechanisms of drug resistance. Methods: We resolved the cellular composition, underlying transcriptional inter- and

APA, Harvard, Vancouver, ISO, and other styles

25

Maeding, Nicole, Daniela Asslaber, Nadja Zaborsky, Andreas Villunger, Richard Greil, and Alexander Egle. "Lack of Bmf Facilitates the Selection of Highly Responsive B-Cell Receptor Clones in Chronic Lymphocytic Leukemia." Blood 138, Supplement 1 (2021): 1543. http://dx.doi.org/10.1182/blood-2021-152216.

Full text

Abstract:

Abstract Introduction: Chronic lymphocytic leukemia (CLL) is a disease of inhibited cell death, increased proliferation and high importance of interactions with the microenvironment e.g. with T-cells or stromal cells. A central effector in this concert is the activation of B-cell receptor (BCR) signalling pathway, associated with selection of specific BCR qualities (either autonomous signalling or reactivity to chronic (auto)-antigenic stimuli) and these signals play an essential role in CLL disease development and progression, also evidenced by the clinical success of kinase inbibitors direct

APA, Harvard, Vancouver, ISO, and other styles

26

Garg, Tarun K., Ricky D. Edmondson, Shweta S. Chavan, et al. "Differential ICAM3 Gene Expression Correlates with Susceptibility to Natural Killer Cell-Mediated Lysis in Multiple Myeloma." Blood 126, no. 23 (2015): 2990. http://dx.doi.org/10.1182/blood.v126.23.2990.2990.

Full text

Abstract:

Abstract Introduction We previously reported on the generation of highly activated/expanded natural killer cells (ENKs) after coculture with K562 cells modified to express membrane bound IL15 and 41BB-ligand. These cells have potent antimyeloma properties in vitro, in a NGS mouse model, and are safe when given to advanced multiple myeloma (MM) patients. (Szmania et al, J Immunother 2015) A potential obstacle to the effectiveness of ENK-based immunotherapy of MM is the evasion of immune recognition. We have generated 4 MM cell lines (OPM2, JJN3, ANBL6, and INA-6) which are resistant to ENK-medi

APA, Harvard, Vancouver, ISO, and other styles

27

Sun, Xubin, Jingjing Li, Wei Zhang, Guiyang Sun, Xiyao Zhang, and Hongze Xu. "Two-Step Optimization Method of Freight Train Speed Curve Based on Rolling Optimization Algorithm and MPC." Vehicles 7, no. 1 (2025): 17. https://doi.org/10.3390/vehicles7010017.

Full text

Abstract:

Given the considerable length and weight of freight trains, their operation can be quite challenging. Improper operation may lead to train decoupling and derailment. Driver Advisory Systems (DASs) are used in some countries to assist train drivers by providing the speed curves, which are desired to be easy to track. Multi-mass train model is a good choice to depict the in-train forces in train speed curve generating, but its application is often hindered by the computation time. A single mass train model is considered as another choice to simplify the computation. To exploit the advantages of

APA, Harvard, Vancouver, ISO, and other styles

28

Tarantino, Michael D., Michael Vredenburg, Wei Tian, Brian Jamieson, and Kashyap B. Patel. "Efficacy Analyses from the Immune Thrombocytopenia (ITP) Clinical Development Program for Avatrombopag: Comparisons with Placebo and Eltrombopag." Blood 136, Supplement 1 (2020): 23–24. http://dx.doi.org/10.1182/blood-2020-142788.

Full text

Abstract:

Background: Management of ITP following failure of 1st line therapy, such as corticosteroids or intravenous immunoglobulin, continues to evolve. The use of thrombopoietin receptor agonists (TPO-RAs) as a subsequent therapeutic approach has become more common, which is supported by the recent American Society of Hematology guidelines (Neunert 2019). The oral TPO-RA eltrombopag (ELT) has an established efficacy profile but also carries an FDA boxed safety warning for hepatotoxicity, necessitating hepatic function monitoring. Additionally, ELT acts as a chelating agent, thus requiring administrat

APA, Harvard, Vancouver, ISO, and other styles

29

Mehr, Shaadi, Daniel Auclair, Mark Hamilton, et al. "Architecture of Sample Preparation and Data Governance of Immuno-Genomic Data Collected from Bone Marrow and Peripheral Blood Samples Obtained from Multiple Myeloma Patients." Blood 136, Supplement 1 (2020): 17–18. http://dx.doi.org/10.1182/blood-2020-142882.

Full text

Abstract:

Abstract: Title: Architecture of sample preparation and data governance of Immuno-genomic data collected from bone marrow and peripheral blood samples obtained from multiple myeloma patients In multiple myeloma (MM), the interactions between malignant plasma cells and the bone marrow microenvironment is crucial to fully understand tumor development, disease progression, and response to therapy. The core challenge in understanding those interactions has been the establishment of a standard process and a standard model for handling the data quality workflow and the underlying data models. Here w

APA, Harvard, Vancouver, ISO, and other styles

30

White, Brian S., Suleiman A. Khan, Muhammad Ammad-ud-din, et al. "Comparative Analysis of Independent Ex Vivo functional Drug Screens Identifies Predictive Biomarkers of BCL-2 Inhibitor Response in AML." Blood 132, Supplement 1 (2018): 2763. http://dx.doi.org/10.1182/blood-2018-99-111916.

Full text

Abstract:

Abstract Introduction: Therapeutic options for patients with AML were recently expanded with FDA approval of four drugs in 2017. As their efficacy is limited in some patient subpopulations and relapse ultimately ensues, there remains an urgent need for additional treatment options tailored to well-defined patient subpopulations to achieve durable responses. Two comprehensive profiling efforts were launched to address this need-the multi-center Beat AML initiative, led by the Oregon Health & Science University (OHSU) and the AML Individualized Systems Medicine program at the Institute for M

APA, Harvard, Vancouver, ISO, and other styles

31

Mishima, Yuji, Michele Moschetta, Jiantao Shi, et al. "Clonal-Heterogeneity and Propensity for Bone Metastasis in Multiple Myeloma." Blood 124, no. 21 (2014): 3370. http://dx.doi.org/10.1182/blood.v124.21.3370.3370.

Full text

Abstract:

Abstract Rationale Multiple Myeloma (MM) is characterized by the presence of multiple disease foci disseminated throughout the skeleton suggesting continuous circulation and metastasis of myeloma cells from one site of the bone marrow (BM) to another leading disease progression. However the metastatic process in MM has not been well characterized. In addition, the role of specific subclones that have the propensity for metastasis and tumor colonization in the BM niche has not been investigated. In this study, we developed a new BM metastasis xenograft model to examine clonal heterogeneity in t

APA, Harvard, Vancouver, ISO, and other styles

32

Spencer, Andrew, Tiffany Khong, and Maoshan Chenn. "MCL-1 Inhibitor-Induced Killing of Multiple Myeloma Is Modulated By the Relative Level of Expression of Pro-Survival Members of the BCL-2 Family and the Proto-Oncogene MYC." Blood 134, Supplement_1 (2019): 1825. http://dx.doi.org/10.1182/blood-2019-127843.

Full text

Abstract:

Background: The anti-apoptotic protein Myeloid cell leukemia sequence 1 (MCL-1) is involved in the regulation of programmed cell death and is highly expressed in multiple myeloma (MM) playing an important role in promoting the survival of MM cells. Recent data suggests that the efficacy against MM of the selective BCL-2 inhibitor Venetoclax (V) may be correlated with the relative level of expression of the pro-survival members of the BCL-2 protein family. Against this background we have evaluated the activity of the MCL-1 inhibitor (MCL1i) S63845 (S) against human myeloma cell lines (HMCL) and

APA, Harvard, Vancouver, ISO, and other styles

33

Wang, Tianjiao, Hua Sun, Daniel Cui Zhou, et al. "Single-Cell Pathway Enrichment and Regulatory Profiling of Multiple Myeloma across Disease Stages." Blood 134, Supplement_1 (2019): 364. http://dx.doi.org/10.1182/blood-2019-131361.

Full text

Abstract:

Multiple myeloma (MM) is a hematological malignancy, defined by aberrant monoclonal proliferation of plasma cells in the bone marrow, that to date remains an incurable disease despite advances in treatment. Key genetic and epigenetic alterations that drive MM pathogenesis have been identified, but a comprehensive profile of affected cellular pathways has yet to be fully characterized. In this study, we integrate whole-genome and whole-exome sequencing data with single-cell RNA sequencing (scRNA-seq) data from 13 patients across multiple treatment stages to 1) assess differential pathway enrich

APA, Harvard, Vancouver, ISO, and other styles

34

Matino, Davide, Giancarlo Castaman, Giovanni Di Minno, et al. "Prospective Study of the Immunological Mechanisms of Immune Tolerance Induction in Severe Haemophilia a Patients with Inhibitors: Preliminary Analysis of a Multi-Center Longitudinal Study." Blood 132, Supplement 1 (2018): 3781. http://dx.doi.org/10.1182/blood-2018-99-119568.

Full text

Abstract:

Abstract Background The development of an immunogenic response to FVIII and the appearance of neutralizing antibodies - "inhibitors" - against FVIII is the most important adverse event in hemophilia treatment. Immune Tolerance Induction (ITI) via the long-term, intravenous administrations of high-dose FVIII is the only proven strategy to eradicate inhibitors. The success rate is about 60-70% and no formal demonstration of its mechanism of action has been provided yet. Indeed, the mechanisms underlying successful ITI have been unclear, and not much is known about the major factors determinant o

APA, Harvard, Vancouver, ISO, and other styles

35

Wallace, Sarah, Victoria Hall, Andre Charlett, et al. "Impact of prior SARS-CoV-2 infection and COVID-19 vaccination on the subsequent incidence of COVID-19: a multicentre prospective cohort study among UK healthcare workers – the SIREN (Sarscov2 Immunity & REinfection EvaluatioN) study protocol." BMJ Open 12, no. 6 (2022): e054336. http://dx.doi.org/10.1136/bmjopen-2021-054336.

Full text

Abstract:

Introduction Understanding the effectiveness and durability of protection against SARS-CoV-2 infection conferred by previous infection and COVID-19 is essential to inform ongoing management of the pandemic. This study aims to determine whether prior SARS-CoV-2 infection or COVID-19 vaccination in healthcare workers protects against future infection. Methods and analysis This is a prospective cohort study design in staff members working in hospitals in the UK. At enrolment, participants are allocated into cohorts, positive or naïve, dependent on their prior SARS-CoV-2 infection status, as measu

APA, Harvard, Vancouver, ISO, and other styles

36

Lee, Shawn, Federico Antillón, Deqing Pei, et al. "The Impact of Genetic Ancestry on the Biology and Prognosis of Childhood Acute Lymphoblastic Leukemia." Blood 138, Supplement 1 (2021): 3476. http://dx.doi.org/10.1182/blood-2021-145655.

Full text

Abstract:

Abstract INTRODUCTION Acute lymphoblastic leukemia (ALL) is the most common cancer in children. Despite improvements in treatment over the past few decades, stark racial disparities persist in disease risk and cure rates. There is a paucity of data describing the genetic basis of these disparities, especially in relation to modern ALL molecular taxonomy and in the context of contemporary treatment regimens. To this end, we sought to determine the associations of genetic ancestry with ALL biology, and the relevance of genetic ancestry to survival outcomes of modern ALL therapy. METHODS This was

APA, Harvard, Vancouver, ISO, and other styles

37

Sauer, Sandra, Christos Sachpekidis, Simone Brandelik, et al. "Prospective Evaluation of 18-F FDG PET/CT and Biopsies of Osteolytic Lesions and Random Bone Marrow Samples in Newly Diagnosed Multiple Myeloma Patients." Blood 132, Supplement 1 (2018): 3180. http://dx.doi.org/10.1182/blood-2018-99-115201.

Full text

Abstract:

Abstract Background The degree of plasma cell (PC) infiltration in the bone marrow (BM) is an important diagnostic and prognostic marker in multiple myeloma. An infiltration of 60% or more has been included into the new criteria of the IMWG defining myeloma. PC infiltration can vary significantly within and among individual patients regarding growth patterns (focal, diffuse or mixed), bone destruction (best visible in CT), which may or may not be concomitantly present, and levels of PC metabolism (best detected by PET). Usually, BM examinations are performed by random biopsy and aspirate from

APA, Harvard, Vancouver, ISO, and other styles

38

Roter, Kyle, Donglei Hu, Alyssa Clay-Gilmour, et al. "Germline Variation Predicts Treatment Response in Multiple Myeloma." Blood 134, Supplement_1 (2019): 4397. http://dx.doi.org/10.1182/blood-2019-129344.

Full text

Abstract:

Background: Multiple myeloma (MM) treatment has advanced considerably with proteasome inhibitors, immunomodulatory drugs (IMiDs), and, most recently, monoclonal antibodies. However, treatment response is quite heterogeneous, and many patients still progress even with novel combination therapies. Thus, understanding the factors that underlie response to treatment is a priority. Several somatic genomic aberrations and mutations predict poor response to therapy. However, germline variation has not previously been investigated as a predictor of treatment response in MM. We used genome-wide associa

APA, Harvard, Vancouver, ISO, and other styles

39

Poos, Alexandra M., Jan-Philipp Mallm, Stephan M. Tirier, et al. "A Comprehensive Analysis of Single-Cell Chromatin Accessibility and Gene Expression Identifies Intra-Tumor Heterogeneity and Molecular Treatment Responses in Relapsed/Refractory Multiple Myeloma." Blood 134, Supplement_1 (2019): 575. http://dx.doi.org/10.1182/blood-2019-130051.

Full text

Abstract:

Introduction: Multiple myeloma (MM) is a heterogeneous malignancy of clonal plasma cells that accumulate in the bone marrow (BM). Despite new treatment approaches, in most patients resistant subclones are selected by therapy, resulting in the development of refractory disease. While the subclonal architecture in newly diagnosed patients has been investigated in great detail, intra-tumor heterogeneity in relapsed/refractory (RR) MM is poorly characterized. Recent technological and computational advances provide the opportunity to systematically analyze tumor samples at single-cell (sc) level wi

APA, Harvard, Vancouver, ISO, and other styles

40

Coffey, David G., Francesco Maura, Edgar Gonzalez-Kozlova, et al. "Normalization of the Immune Microenvironment during Lenalidomide Maintenance Is Associated with Sustained MRD Negativity in Patients with Multiple Myeloma." Blood 138, Supplement 1 (2021): 329. http://dx.doi.org/10.1182/blood-2021-154506.

Full text

Abstract:

Abstract Background: The progression of multiple myeloma (MM) during ongoing therapy is driven by a complex interplay between tumor cells and their surrounding immune microenvironment. We were motivated to conduct a comprehensive and orthogonal investigation of the cellular and humoral immunity of patients with MM treated with lenalidomide maintenance therapy. We compared patients who achieved sustained minimal residual disease (MRD) negativity during the first year of maintenance therapy to those who lost or were unable to attain an MRD negative state. Methods: As part of our prospective phas

APA, Harvard, Vancouver, ISO, and other styles

41

Sheih, Alyssa, Jonathan L. Golob, Abir Bhattacharyya, et al. "Impact of Intestinal Microbiota on Reconstitution of Mucosal-Associated Invariant T Cells after Allogeneic Hematopoietic Stem Cell Transplantation." Blood 132, Supplement 1 (2018): 3393. http://dx.doi.org/10.1182/blood-2018-99-115158.

Full text

Abstract:

Abstract INTRODUCTION: Mucosal-associated invariant T (MAIT) cells are innate-like T cells that express a semi-invariant T cell receptor (TCR) consisting of a Vα7.2 chain paired with a restricted repertoire of Vβ chains. The MAIT cell TCR recognizes riboflavin metabolites, and potentially other ligands produced by distinct bacterial and fungal species and presented in the context of the MHC class I-related molecule (MR1). MAIT cells are abundant in humans, comprising up to 10% of T cells in the peripheral blood, and are enriched in the gastrointestinal (GI) mucosa and liver. The GI localizatio

APA, Harvard, Vancouver, ISO, and other styles

42

McCarthy, John J. "Alan S. Kaye (ed.) (1997). Phonologies of Asia and Africa (including the Caucasus). Technical advisor: Peter T. Daniels. Winona Lake, Indiana: Eisenbrauns. 2 vols. Pp. xxi+1041." Phonology 15, no. 1 (1998): 111–14. http://dx.doi.org/10.1017/s0952675798003509.

Full text

Abstract:

This is an unusual book. For one thing, it is huge: two volumes, over 1000 pages, with articles on fifty different languages or groups. For another, the list of contributors is quite diverse, including a few phonologists with specific language interests (Shmuel Bolozky, Robert D. Hoberman, Maria-Rosa Lloret and Joseph L. Malone), a few linguists who are better known for their work in areas other than phonology (Bernard Comrie, Jeffrey Heath, H. Craig Melchert and Johanna Nichols) and a group of distinguished experts on particular languages or families (including Giorgio Buccellati, Gene Gragg,

APA, Harvard, Vancouver, ISO, and other styles

43

Arkian, Muhammad Reyzha Noorsyam, M. Subur Drajat, and Dadi Ahmadi. "Peran Public Relations dalam Film Hancock." Inter Komunika : Jurnal Komunikasi 3, no. 2 (2018): 145. http://dx.doi.org/10.33376/ik.v3i2.214.

Full text

Abstract:

Abstract. Film is a mass media that has a function as entertainment, besides that the film also contains an informative, educative, and persuasive function. Film is also known as a medium of communication, film is an effective means to shape the perspective of society at large. A movie titled “Hancock” is a movie about a public relations practitioner who tries to restore the image of a superhero. This movie also tells a story about the troublesome life of a superhero who has bad image in the eyes of public and media. The purpose of this research is to understand the Reality Level, Representati

APA, Harvard, Vancouver, ISO, and other styles

44

Decroocq, Justine, Rudy Birsen, Jordi Mano, et al. "Combination of the MEK Inhibitor Trametinib and Pyrvinium Pamoate Efficiently Targets RAS Pathway-Mutated Acute Myeloid Leukemia in Preclinical Models." Blood 134, Supplement_1 (2019): 2671. http://dx.doi.org/10.1182/blood-2019-123418.

Full text

Abstract:

While acute myeloid leukemia (AML) is still associated with a low cure rate, recent advances in understanding its molecular complexity have significantly improved therapy for subgroups of patients, including those harboring FLT3, IDH1 or IDH2 mutations1. However, more than half of AML cases still lack a druggable oncogenic target. Human cancers frequently harbor mutations in RAS oncogene family members, including NRAS, KRAS and HRAS, which drive oncogenesis by augmenting cellular proliferation and survival. These are small protein GTPases, regulated by a switch between active GTP-linked and in

APA, Harvard, Vancouver, ISO, and other styles

45

Zhang, Haiyu, Bing Zhang, Xiangqian Guo, et al. "Effects of Thrombopoietin Mimetics on Patients with Chronic ITP: Perspectives from Blood Transcriptome Profiling Analysis." Blood 124, no. 21 (2014): 2780. http://dx.doi.org/10.1182/blood.v124.21.2780.2780.

Full text

Abstract:

Abstract Introduction: Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by low platelet counts due to accelerated platelet destruction and impaired platelet production. Thrombopoietin (TPO) is the major regulator of platelet production, and TPO mimetics have been approved to treat patients with ITP with a response rate around 80%. In this study, we assessed the impact of eltrombopag on patients at the RNA level and explored the biological mechanisms underlying the variations in individual responses through blood transcriptome profiling analysis. Methods: Peripheral blood s

APA, Harvard, Vancouver, ISO, and other styles

46

Bai, Xiaoying, Jennifer Trowbridge, Joseph Lee, Stuart H. Orkin, and Leonard I. Zon. "Analysis of TIF1gamma Conditional Knockout Establishes a Requirement for the Differentiation of Multiple Hematopoietic Lineages." Blood 116, no. 21 (2010): 744. http://dx.doi.org/10.1182/blood.v116.21.744.744.

Full text

Abstract:

Abstract Abstract 744 Vertebrate hematopoiesis is regulated by cell-specific transcription factors that couple to RNA polymerase-associated basal machinery. Mutation of the chromatin factor TIF1gamma (TIF1g) gene in the zebrafish moonshine mutant causes a profound decrease in expression of most erythroid genes. Our previous work in the zebrafish system established an essential role of TIF1g in transcription elongation by coupling the SCL transcription factor complex to the transcription elongation machinery, and erythroid-specific transcription is paused in moonshine mutant (Bai et al., Cell 2

APA, Harvard, Vancouver, ISO, and other styles

47

Sharma, Priyanka, Sujan Piya, Huaxian Ma, et al. "ERK1/2 Inhibition Overcomes Resistance in Acute Myeloid Leukemia (AML) and Alters Mitochondrial Dynamics." Blood 138, Supplement 1 (2021): 3338. http://dx.doi.org/10.1182/blood-2021-151579.

Full text

Abstract:

Abstract Background: Presence at diagnosis or acquisition of activating RAS pathway mutations is a pervasive mechanism of resistance to therapy in AML. Efforts to directly target mutant RAS have been unsuccessful and the efficacy of BRAF and MEK inhibitors has been limited due to compensatory reactivation of MAPK signaling. ERK1/2 (ERK) is a key downstream component in the MAPK pathway and therefore represents an attractive target for inhibiting MAPK signaling. Compound 27 (1) is a dual-mechanism inhibitor of ERK that inhibits both the catalytic activity of ERK and its phosphorylation by MEK.

APA, Harvard, Vancouver, ISO, and other styles

48

Stahlberg, Eric, Lynn Borkon, Ruth Frost, et al. "Abstract 7432: Improving FAIRness of computational approaches for cancer: The computational resources for cancer research portal." Cancer Research 84, no. 6_Supplement (2024): 7432. http://dx.doi.org/10.1158/1538-7445.am2024-7432.

Full text

Abstract:

Abstract The Computational Resources for Cancer Research website is a public portal supported by NCI that democratizes access to available computational resources for the cancer research community. In supporting an emerging FAIR (Findable, Accessible, Interoperable, Reusable) data science ecosystem inclusive of software, models and data, the goals of the portal are to serve cancer data scientists by increasing understanding, access, and adoption of computational resources for cancer research, and to foster new collaborative research projects. Initially populated with resources developed in NCI

APA, Harvard, Vancouver, ISO, and other styles

49

Kumar, Ashwini, Muntasir Mamun Majumder, Jesus María Lopez Martí, et al. "The Use of RNA Sequencing to Identify Disease-Specific Gene Expression Signatures and Critical Regulatory Networks Across Hematologic Malignancies." Blood 124, no. 21 (2014): 2203. http://dx.doi.org/10.1182/blood.v124.21.2203.2203.

Full text

Abstract:

Abstract Introduction Transcriptome analysis by next-generation sequencing (RNA-seq) allows investigation of hematologic malignancies at unsurpassed resolution and provides promising insights into their molecular etiology. Dissecting the underlying biology depends on specific molecular signatures deregulated in the disease subtypes. In addition, gene expression profiles may potentially be used to identify driver genetic alterations and stratify patients based on molecular subtype. In this study, we generated gene expression profiles from RNA-seq data derived from patients with hematologic dise

APA, Harvard, Vancouver, ISO, and other styles

50

Chen, Zhenghao, Gaspard Cretenet, Beatriz Valle-Argos, et al. "Effects of Ibrutinib on Metabolic Alterations and Micro-Environmental Signalling in Chronic Lymphocytic Leukaemia." Blood 136, Supplement 1 (2020): 36–37. http://dx.doi.org/10.1182/blood-2020-142839.

Full text

Abstract:

Introduction. Altered metabolism is one of the hallmarks of cancer. CLL cells circulate between peripheral blood (PB) and lymph nodes (LN) which necessitates high metabolic plasticity. In LN, CLL cells receive proliferative and pro-survival signals from surrounding cells, and become metabolically activated. However, detailed insight into the altered metabolism of LN CLL and how this may be related to therapeutic responses is lacking. As it is technically difficult to obtain direct insight into CLL LN metabolism, we have applied a two-tiered strategy. By using PB samples taken from patients bef

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!